Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 8/20 | 0.59 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28406437 | 1.00 | MBOAT4 (0.59) | MBOAT4BACE1CTSDKDM4EPKM | |
| SCHEMBL28406440 | 1.00 | MBOAT4 (0.59) | MBOAT4BACE1CTSDKDM4EPKM | |
| SCHEMBL16699034 | 0.96 | MBOAT4 (0.63) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL19971822 | 0.86 | MBOAT4 (0.64) | MBOAT4FAAH | |
| SCHEMBL19971821 | 0.86 | MBOAT4 (0.64) | MBOAT4FAAH | |
| SCHEMBL18166194 | 0.85 | MBOAT4 (0.80) | MBOAT4 | |
| SCHEMBL19971797 | 0.85 | MBOAT4 (0.80) | MBOAT4 | |
| SCHEMBL19971798 | 0.85 | MBOAT4 (0.80) | MBOAT4 | |
| SCHEMBL20009391 | 0.85 | MBOAT4 (0.50) | MBOAT4KDM4EPKMFAAHGPR119 | |
| SCHEMBL16699845 | 0.84 | MBOAT4 (0.49) | MBOAT4BACE1KDM4EPKMFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885BACE1 1257/4885CTSD 2104/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885BACE1 1257/4885CTSD 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.